Target intelligence / Profile preview

Patient-specific tumor neoantigen–derived peptide–Major Histocompatibility Complex (pMHC) on dendritic cells (Neoantigen-pMHC on DCs)

Target
Neoantigen-pMHC on DCs
Molecular classification
Protein complex, Antigen-presenting complex, Major Histocompatibility Complex (MHC)
01

Overview

Patient-specific tumor neoantigen–derived peptide–MHC complexes on dendritic cells are the fundamental units of recognition for the adaptive immune system in personalized oncology (Sahin et al., Nature, 2017). These complexes consist of neoantigens—peptides derived from somatic mutations unique to a patient's tumor—bound to Major Histocompatibility Complex (MHC) molecules on the surface of professional antigen-presenting cells like dendritic cells (Hu et al., Nature Reviews Immunology, 2021). Their primary biological function is to present these 'non-self' signals to naive T cells, thereby priming a targeted immune response against malignant cells (Ott et al., Nature, 2017). In therapeutic applications, such as personalized neoantigen vaccines, these complexes are utilized to expand the repertoire of tumor-infiltrating lymphocytes (TILs) and overcome immune tolerance (Blass & Ott, Nature Reviews Clinical Oncology, 2021). By focusing on mutations absent from healthy tissue, drugs targeting these complexes aim to minimize off-target toxicity while maximizing anti-tumor efficacy (NCI, 2023). This approach is currently being evaluated in various solid tumors, including melanoma and lung cancer, often in combination with checkpoint inhibitors to enhance the durability of the immune response (Moderna, 2024).

Other names
Personalized neoantigen-MHC complexesTumor-specific neoepitope-HLA complexesNeoantigen-presenting dendritic cellspMHC complexesTSA-MHC complexes
02

Mechanism of action

The mechanism involves the interaction between the neoantigen-pMHC complex and the T-cell receptor (TCR). Dendritic cells present the neoantigen via MHC Class I to CD8+ T cells and MHC Class II to CD4+ T cells, leading to the activation, proliferation, and differentiation of these cells into effector T cells that can specifically recognize and lyse tumor cells expressing the same neoantigen (Nature Reviews Cancer, 2021; Sahin et al., Nature, 2017).

03

Biological functions

Antigen presentationT-cell activationImmune responseAdaptive immunity
04

Disease associations

CancerMelanomaNon-small cell lung cancerPancreatic cancerSolid tumors
05

Safety considerations

Immune-related adverse events (irAEs)Tumor antigen loss or heterogeneity leading to immune escapeLogistical challenges and delays in personalized manufacturingPotential for cross-reactivity with self-antigens if prediction algorithms fail
06

Interacting drugs

mRNA-4157 (V940)

4 more in the full profile.

07

Biomarkers

Tumor Mutational Burden (TMB)HLA-A/B/C and HLA-DR/DQ/DP typingNeoantigen fitness scoresT-cell receptor (TCR) sequencingInterferon-gamma (IFN-γ) expression

Beyond the preview

Go deeper on Patient-specific tumor neoantigen–derived peptide–Major Histocompatibility Complex (pMHC) on dendritic cells (Neoantigen-pMHC on DCs).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Patient-specific tumor neoantigen–derived peptide–Major Histocompatibility Complex (pMHC) on dendritic cells (Neoantigen-pMHC on DCs).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call